You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Integrase Inhibitors

Showing 1 - 25 of 4,287
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HIV I Infection, Cardiovascular Risk Factor, Lipid Metabolism Disorders Trial (Doravirine 100 Mg)

Recruiting
  • HIV I Infection
  • +2 more
  • Doravirine 100 Mg
  • Los Angeles, California
  • +1 more
Nov 1, 2022

Gut Microbiota, PGx and INSTIs Response

Recruiting
  • HIV Infections
  • Brussels, Belgium
    Cliniques universitaires Saint-Luc
Jan 16, 2023

HIV Trial in United States (Doravirine 100 Mg, Tenofovir alafenamide/emtricitabine, tenofovir alafenamide/lamivudine)

Recruiting
  • HIV Infections
  • Doravirine 100 Mg
  • +5 more
  • Birmingham, Alabama
  • +22 more
Feb 22, 2022

Metabolic Effects, Weight Gain, HIV Trial run by the National Institute of Allergy and Infectious Diseases (NIAID) (Tenofovir

Not yet recruiting
  • Metabolic Effects
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

HIV-1-infection, Multi-Antiviral Resistance Trial in Milan (REGISTER CREATION)

Recruiting
  • HIV-1-infection
  • Multi-Antiviral Resistance
  • REGISTER CREATION
  • Milan, MI, Italy
    Ospedale San Raffaele
Dec 22, 2021

Hiv, Weight Gain Trial in Toronto (DOR/3TC/TDF)

Enrolling by invitation
  • Hiv
  • Weight Gain
  • Toronto, Ontario, Canada
    University Health Network
May 17, 2022

HIV-1-infection Trial in Kenya (Dolutegravir)

Completed
  • HIV-1-infection
  • Kiambu, Kenya
  • +3 more
Jan 26, 2022

HIV I Infection, Adiposity Trial in Saint Louis (Frequently sampled glucose tolerance testing, abdominal subcutaneous adipose

Recruiting
  • HIV I Infection
  • Adiposity
  • Frequently sampled glucose tolerance testing
  • +2 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Jun 15, 2022

PRJ2203: Dolutegravir Post Authorization Safety Study (PASS)

Completed
  • Infection, Human Immunodeficiency Virus I
  • DTG based ARV regimen with ABC
  • +4 more
  • (no location specified)
Feb 5, 2020

HIV/AIDS Trial in Worldwide (Biktarvy, Symtuza)

Recruiting
  • HIV/AIDS
  • Antwerp, Belgium
  • +47 more
Jan 9, 2023

Raltegravir and Darunavir/Ritonavir in HIV Infected Patients.

Completed
Has Results
  • Integrase Inhibitors, HIV; HIV PROTEASE INHIB
  • Barcelona, Spain
    Hospital Clinic
Aug 29, 2019

NNRTI or INSTI on Nonalcoholic Steatosis in HIV/AIDS Patients

Not yet recruiting
  • Nonalcoholic Fatty Liver Disease
  • +3 more
    • (no location specified)
    Apr 18, 2022

    HIV-1-infection Trial (Delstrigo, KOCITAF)

    Not yet recruiting
    • HIV-1-infection
    • (no location specified)
    Jun 20, 2023

    Primary Resistance in HIV Patients in Colombia

    Recruiting
    • HIV Infection
    • HIV-1 plasma RNA Genotyping secuencing by Sanger technique
    • HIV-1 plasma RNA Genotyping secuencing by Ultra-deep sequencing technique
    • Cali, Valle, Colombia
      REVIVA, Red de VIH del Valle del Cauca
    Jan 17, 2022

    Bictegravir in the Elderly Living With HIV (BICEP)

    Active, not recruiting
    • HIV-1-infection
    • Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]
    • Buffalo, New York
      Evergreen Health
    Oct 28, 2022

    Assess the ART Impact on the Brain Outcomes. The ARBRE Study

    Completed
    Has Results
    • HIV-1 Infection
    • Cognitive Impairment
      • (no location specified)
      May 15, 2020

      Human Immunodeficiency Virus Trial in Oakland Park (Symtuza)

      Terminated
      • Human Immunodeficiency Virus
      • Oakland Park, Florida
        Midland Research Group, Inc
      Dec 3, 2021

      Intensive Viral Dynamics Substudy of A5248

      Completed
      • HIV Infections
      • Treatment Naive
        • Aurora, Colorado
        • +5 more
        Oct 28, 2021

        HIV-1 Infection Trial in France (Samplings)

        Recruiting
        • HIV-1 Infection
        • Samplings
        • Clamart, France
        • +6 more
        Jan 4, 2022

        HIV-1-infection, HIV, PD-L1 Gene Mutation Trial in Beijing (ASC22 1mg/kg, ASC22 2.5mg/kg, Antiretroviral Therapy)

        Recruiting
        • HIV-1-infection
        • +2 more
        • ASC22 1mg/kg
        • +3 more
        • Beijing, Beijing, China
          The FifthMedical Center of the General Hospital of thePeoples Li
        Jun 28, 2022

        HIV Trial in Sevilla (Continue with triple therapy, Switch to DTG + 3TC, Switch to DRV/cobicistat + 3TC)

        Completed
        • HIV Infections
        • Continue with triple therapy
        • +2 more
        • Sevilla, Spain
          Virgen del Rocio University Hospital
        Aug 27, 2021

        HIV-1-infection Trial (Bictegravir, Lenacapavir, BIC/LEN FDC)

        Not yet recruiting
        • HIV-1-infection
        • (no location specified)
        Aug 12, 2022

        HIV, Clinical Outcomes, Adverse Drug Event Trial in Salvador, São Paulo (No intervention)

        Recruiting
        • HIV Infections
        • +3 more
        • No intervention
        • Salvador, Bahia, Brazil
        • +2 more
        Mar 15, 2022

        HIV Trial in Baltimore (Switch to Maraviroc + Raltegravir or Dolutegravir)

        Completed
        Has Results
        • HIV
        • Switch to Maraviroc + Raltegravir or Dolutegravir
        • Baltimore, Maryland
          University of Maryland, Institute of Human Virology
        Oct 5, 2021

        Effect on HIV Medications on EPC Cells

        Completed
        • AIDS
        • Washington, District of Columbia
          The GW Medical Faculty Associates
        Mar 21, 2022